| 79.75 1.64 (2.1%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 95.63 | 1-year : | 100.84 |
| Resists | First : | 81.88 | Second : | 86.33 |
| Pivot price | 80.08 |
|||
| Supports | First : | 74.66 | Second : | 62.12 |
| MAs | MA(5) : | 77.9  |
MA(20) : | 79.55 |
| MA(100) : | 85.58 |
MA(250) : | 77.56 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 28.9 |
D(3) : | 23.3 |
| RSI | RSI(14): 49.4 |
|||
| 52-week | High : | 101.4 | Low : | 51.79 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GMED ] has closed above bottom band by 47.1%. Bollinger Bands are 0.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 80.7 - 81.03 | 81.03 - 81.36 |
| Low: | 76.65 - 76.98 | 76.98 - 77.32 |
| Close: | 79.2 - 79.78 | 79.78 - 80.39 |
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
Sun, 12 Jul 2026
Barclays Maintains Globus Medical (GMED) Overweight Recommendation - MSN
Fri, 10 Jul 2026
Globus Medical Inc - A (NYSE:GMED) Screens Well as a GARP Stock with Strong Growth and Reasonable Valuation - ChartMill
Wed, 08 Jul 2026
A Look at Globus Medical Inc (GMED) After 3.3% Decline -- GF Val - GuruFocus
Wed, 08 Jul 2026
Globus Medical (GMED) Receives Positive Coverage from BMO Capita - GuruFocus
Tue, 07 Jul 2026
Globus Medical (GMED) Rose With Device Stocks, Is It Still 27% Undervalued? - Yahoo Finance
Sat, 27 Jun 2026
Globus Medical (GMED) Stock After 47% One-Year Gain Is There More Room To Run - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 113 (M) |
| Shares Float | 112 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 101.6 (%) |
| Shares Short | 7,410 (K) |
| Shares Short P.Month | 3,920 (K) |
| EPS | 4.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 34.88 |
| Profit Margin | 18.9 % |
| Operating Margin | 21.3 % |
| Return on Assets (ttm) | 8.1 % |
| Return on Equity (ttm) | 13.3 % |
| Qtrly Rev. Growth | 27 % |
| Gross Profit (p.s.) | 18.7 |
| Sales Per Share | 27.35 |
| EBITDA (p.s.) | 8.34 |
| Qtrly Earnings Growth | 66.6 % |
| Operating Cash Flow | 779 (M) |
| Levered Free Cash Flow | 341 (M) |
| PE Ratio | 18.63 |
| PEG Ratio | 1.4 |
| Price to Book value | 2.28 |
| Price to Sales | 2.91 |
| Price to Cash Flow | 11.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|